Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis

Exclusion Criteria

• •Subfoveal NCV due tp presumed ocular histoplasmosis for \> 1 year
• •Pregnancy or lactation premenopausal women not using adequate contraception
• •Prior enrollment in the study
• •Any other condition that the Investigator believes would pose a significant hazard to the subject
• •Participation in another simultaneous medical investigation or trial
• •Participation in another trial or previous trial of ranibizumab or Avastin
• •Any concurrent ocular condition in the study eye (cataract, diabetic retinopathy)that could require medical or surgical intervention or ifa allowed to progress, could likely contribute to loss of at least 2 Snellen equivalent lines of BCVA over the 12-month study period
• •Previous panretinal photocoagulation
• •Previous steroids or PDT in 3 months
• •Previous participation in any studies of investigational drugs within 30 days preceding Day 0
• •Prior participation in a Genentech ranibizumab clinical trial
• •Previous treatment with intravitreally (in either eye) or intravenously administered Avastin within 3 months
• •Previous use of Macugen in the study eye within 3 months
• •Prior submacular surgery